Brief: Equillium's Partner Biocon Initiates Phase 2 Study Of Itolizumab In Ulcerative Colitis
16/12/2022 13:44
Dec 16 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM'S PARTNER BIOCON INITIATES PHASE 2 STUDY OF
ITOLIZUMAB
IN ULCERATIVE COLITIS
* EQUILLIUM INC - BIOCON LIMITED, IN COLLABORATION WITH CO,
HAS
INITIATED PHASE 2 CLINICAL STUDY OF ITOLIZUMAB IN PATIENTS WITH
ULCERATIVE COLITIS
Source text for Eikon: ID:nBw5cJpqma
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations